$0.59
-0.0209[-3.42%]
At close: May 15
$0.59
0[0.00%]
After Hours: 5:06PM EDT
23andMe Holding
(NASDAQ:ME)Latest News for 23andMe Holding Stock (NASDAQ:ME)
23andMe Holding Stock (NASDAQ: ME)
Categories: All
Tuesday, May 14, 2024
Friday, May 10, 2024
Wednesday, April 24, 2024
Thursday, April 18, 2024
- Nasdaq Down 0.5%; Lithium Americas Shares SlideAvi Kapoor - Apr 18, 2024, 2:54PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Apr 18, 2024, 12:31PM
- Crude Oil Edges Lower; Bio-Path Holdings Shares Spike HigherAvi Kapoor - Apr 18, 2024, 12:08PM
- Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's FutureVandana Singh - Apr 18, 2024, 12:06PM
- Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 18, 2024, 11:32AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Apr 18, 2024, 8:09AM
- 23andMe Reveals CEO's Intention To Pursue Potential Take-PrivateBenzinga Newsdesk - Apr 18, 2024, 8:05AM
- 23andMe shares are trading higher after CEO Anne Wojcicki said she is considering a proposal to take the company private.Benzinga Newsdesk - Apr 18, 2024, 7:51AM
- As Reported In Amended 13D Filing Wednesday, 23andMe CEO Anne Wojcicki Told Board She Is Considering Proposal To Take Co PrivateCharles Gross - Apr 18, 2024, 7:18AM
Tuesday, April 16, 2024
Friday, April 05, 2024
Friday, March 29, 2024
Tuesday, March 05, 2024
Monday, March 04, 2024
Monday, February 26, 2024
Sunday, February 18, 2024
Wednesday, February 14, 2024
Monday, February 12, 2024
Thursday, February 08, 2024
- Crude Oil Gains 3%; Kellanova Posts Upbeat ResultsAvi Kapoor - Feb 8, 2024, 2:19PM
- Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Feb 8, 2024, 1:07PM
- Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last WeekAvi Kapoor - Feb 8, 2024, 12:36PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Feb 8, 2024, 12:31PM
- 23andMe shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.Benzinga Newsdesk - Feb 8, 2024, 8:47AM
Wednesday, February 07, 2024
- 23andMe shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.Benzinga Newsdesk - Feb 7, 2024, 5:02PM
- 23andMe Sees FY24 Revenue $215M-$220M Vs $245.448M Est.Benzinga Newsdesk - Feb 7, 2024, 4:52PM
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga Insights - Feb 7, 2024, 4:31PM
- Recap: 23andMe Holding Q3 EarningsBenzinga Insights - Feb 7, 2024, 4:15PM
- 23andMe Holding Q3 Adj EPS $(0.16) Misses $(0.14) Estimate, Sales $44.75M Miss $54.03M EstimateBenzinga Newsdesk - Feb 7, 2024, 4:11PM
- Earnings Scheduled For February 7, 2024Benzinga Insights - Feb 7, 2024, 5:13AM
Tuesday, February 06, 2024
Monday, February 05, 2024
Wednesday, January 31, 2024
- Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDABenzinga Neuro - Jan 31, 2024, 8:38AM
- 23AndMe Announced The FDA Has Cleared The Investigational New Drug Application For 23ME-01473 Intended To Treat Cancer. Phase 1 Study Is Expected To Start In The First Half Of 2024 In Advanced Solid TumorBenzinga Newsdesk - Jan 31, 2024, 7:36AM
Saturday, January 27, 2024
Tuesday, December 19, 2023
- 23andMe shares are trading higher after the company announced the further expansion of the ongoing 23ME-00610 Phase 1/2a study to include an additional 30 patients with advanced neuroendocrine and ovarian cancers, above the original enrollment goals.Benzinga Newsdesk - Dec 19, 2023, 1:13PM
- 23andme Holding Announced The Further Expansion Of The Ongoing 23ME-00610 Phase 1/2a Study To Include An Additional 30 Patients With Advanced Neuroendocrine And Ovarian CancersBenzinga Newsdesk - Dec 19, 2023, 8:08AM
Thursday, December 14, 2023
Wednesday, November 08, 2023
- 23andME Sees FY24 Revenue $240M-$250M Vs $262.87M Est.Benzinga Newsdesk - Nov 8, 2023, 5:51PM
- 23andMe Holding Q2 EPS $(0.16) Misses $(0.14) Estimate, Sales $50.00M Miss $56.80M EstimateBenzinga Newsdesk - Nov 8, 2023, 4:55PM
- Earnings Scheduled For November 8, 2023Benzinga Insights - Nov 8, 2023, 4:21AM